CEP
MACK

Chicago Equity Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Chicago Equity Partners’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,124
Closed -$260K – 825
2016
Q2 		$260K Buy
6,124
+148
+2% +$8.06K 0.01% 579
2016
Q1 		$394K Sell
5,976
-9,781
-62% -$511K 0.01% 509
2015
Q4 		$979K Buy
15,757
+302
+2% +$21.2K 0.03% 363
2015
Q3 		$1.03M Buy
15,455
+13,417
+658% +$1.1M 0.03% 356
2015
Q2 		$198K Sell
2,038
-1,514
-43% -$144K 0.01% 452
2015
Q1 		$332K Buy
3,552
+810
+30% +$68.9K 0.01% 377
2014
Q4 		$244K Sell
2,742
-2,274
-45% -$166K 0.01% 361
2014
Q3 		$346K Buy
5,016
+3,399
+210% +$182K 0.01% 360
2014
Q2 		$92K Buy
+1,617
New +$82.1K ﹤0.01% 434

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Chicago Equity Partners's MACK Position: Q3 2016 in Review

Chicago Equity Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2016, closing a stake of 6,124 shares — an estimated $260K sold.

Chicago Equity Partners first reported a position in MACK in Q2 2014 and held it in 9 quarters. The position peaked at $1.03M in Q3 2015. 128 funds tracked by Wall St. Rank hold MACK as of Q3 2016.

  • Chicago Equity Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Chicago Equity Partners sold 6,124 Merrimack Pharmaceuticals, Inc. shares in Q3 2016, an estimated $260K.
  • Chicago Equity Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 9 quarters.
  • Chicago Equity Partners's Merrimack Pharmaceuticals, Inc. position peaked at $1.03M in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2016.

Based on Chicago Equity Partners's 13F filing for Q3 2016, filed 28 Oct 2016.